Aerosol formulations and aerosol delivery of buprenorphine
US7501113B2 · kind B2 · utility
20Cited by
29References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2003 |
| Grant date | Mar 10, 2009 |
| Priority date | — |
| Expiry date | Feb 23, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A liquid aerosol formulation comprising at least one thermally stable active ingredient selected from the group consisting of buspirone, buprenorphine, triazolam, cyclobenzaprine, zolpidem, pharmaceutically acceptable salts and esters thereof and derivatives thereof. The liquid formulation can include an organic solvent such as propylene glycol and one or more optional excipients. The active ingredient can be present in an amount of 0.01 to 5 wt. % and the formulation can be heated to provide a vapor which forms an aerosol having a mass median aerodynamic diameter of less than 3 μm.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.